Endo To Boost Sales Force Following Frova In-Licensing Deal With Vernalis
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will add about 70-80 reps to its existing sales force base of 230; detailing for the triptan will target specialty care physicians. Endo will make a $40 mil. milestone payment to Vernalis upon FDA approval for a menstrually associated migraine indication.
You may also be interested in...
Vernalis Restructures, Gives Up U.S. Frova Rights To Increase Cash Reserves
UK company's decision to lay off almost half its workforce, divest Parkinson's therapy Apokyn and shut down U.S. operations stems from "not approvable" letter for Frova last fall for menstrual migraine.
Vernalis Restructures, Gives Up U.S. Frova Rights To Increase Cash Reserves
UK company's decision to lay off almost half its workforce, divest Parkinson's therapy Apokyn and shut down U.S. operations stems from "not approvable" letter for Frova last fall for menstrual migraine.
Endo/Vernalis Seek Menstrual Migraine Indication For Frova
sNDA will be filed with FDA in the coming weeks following positive Phase III trial results.